
Intuitive Surgical (ISRG) Stock Forecast & Price Target
Intuitive Surgical (ISRG) Analyst Ratings
Bulls say
Intuitive Surgical is a strong buy with a positive outlook due to its dominance in the soft-tissue robotics market, potential for long-term growth, underpenetrated market opportunity, and impressive recent financial performance with Q2 revenues of $2.89 billion (+18.5% y/y) and adj. GM of 70.0%. The company has also launched new products and has a strong pipeline of potential future offerings. Risks to our positive outlook include competition, procedural and capital purchasing challenges, and changes in government policies, but overall, we believe ISRG's fundamentals remain strong and its premium valuation is justified.
Bears say
Intuitive Surgical is currently facing a slowing US procedure growth rate, impacted by factors such as the Affordable Care Act and the "law of large numbers". Despite management's prudent investment in innovation, such as the extended-use-program, which may lead to procedure growth re-acceleration in the long-term, these investments could also limit and pressure margins. Competition in the robotics surgery market, along with potential risks such as disruptions from COVID-19, slower new product adoption, and delays in new product approvals, could also impact the company's growth potential. While Intuitive Surgical remains a dominant player in the market, the deterioration of its premium valuation and uncertainty in its outlook warrant a negative outlook from a financial analyst.
This aggregate rating is based on analysts' research of Intuitive Surgical and is not a guaranteed prediction by Public.com or investment advice.
Intuitive Surgical (ISRG) Analyst Forecast & Price Prediction
Start investing in Intuitive Surgical (ISRG)
Order type
Buy in
Order amount
Est. shares
0 shares